Quick Answer
COLLEGIUM PHARMACEUTICAL, INC reported Total Revenue of $780.57 million for the year ending 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed an increase of +23.6% in Total Revenue from 2024 to 2025.
- This data is from COLLEGIUM PHARMACEUTICAL, INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $2.17 million | Q2 2017: $3.56 million | Q3 2017: $11.95 million | Q4 2017: $10.79 million | Q1 2018: $63.75 million | Q2 2018: $73.06 million | Q3 2018: $70.18 million | Q4 2018: $73.43 million | Q1 2019: $74.52 million | Q2 2019: $75.04 million | Q3 2019: $72.94 million | Q4 2019: $74.20 million | Q1 2020: $76.51 million | Q2 2020: $78.06 million | Q3 2020: $79.18 million | Q4 2020: $76.27 million | Q1 2021: $87.72 million | Q2 2021: $82.94 million | Q3 2021: $78.84 million | Q4 2021: $27.36 million | Q1 2022: $83.75 million | Q2 2022: $123.55 million | Q3 2022: $127.01 million | Q4 2022: $129.62 million | Q1 2023: $144.77 million | Q2 2023: $135.55 million | Q3 2023: $136.71 million | Q4 2023: $149.75 million | Q1 2024: $144.92 million | Q2 2024: $145.28 million | Q3 2024: $159.30 million | Q4 2024: $181.95 million | Q1 2025: $177.76 million | Q2 2025: $188.00 million | Q3 2025: $209.36 million | Q4 2025: $205.45 million.
- Over the full 10 years of available data (2016 to 2025), COLLEGIUM PHARMACEUTICAL, INC's Total Revenue has grown by 45,520.5%.
- Historical annual values: Fiscal year 2025: $780.57 million | Fiscal year 2024: $631.45 million | Fiscal year 2023: $566.77 million | Fiscal year 2022: $463.93 million | Fiscal year 2021: $276.87 million | Fiscal year 2020: $310.02 million | Fiscal year 2019: $296.70 million | Fiscal year 2018: $280.41 million | Fiscal year 2017: $28.48 million | Fiscal year 2016: $1.71 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: